Workflow
四川汇宇制药股份有限公司关于自愿披露公司产品获得境外上市许可的公告

Group 1 - The company has received overseas marketing approvals for its products, injection paracetamol sodium and injection pemetrexed disodium, from the Dutch Medicines and Healthcare Products Regulatory Agency and the Saudi Food and Drug Authority [1][2] - Injection paracetamol sodium is indicated for the treatment of short-term postoperative pain in adults and has been approved in multiple countries including the UK and the Netherlands, with a registration application submitted in Germany [1] - Injection pemetrexed disodium is used in combination with cisplatin for the first-line treatment of unresectable malignant pleural mesothelioma and locally advanced or metastatic lung cancer, and has received approvals in 14 countries including China, the UK, and Germany, with applications submitted in 10 additional countries [2] Group 2 - The approvals for injection paracetamol sodium and injection pemetrexed disodium enhance the company's product pipeline in international markets, improve brand image, and support the sustainable development of international business [3] - The company has initiated preparations for the sales of these products, but the future revenue generation remains uncertain due to factors such as competition and the effectiveness of business promotion [3]